Thyme Care’s Post

In the latest #oncologyissues — Development and implementation of e-consults for patients experiencing endocrine immune-related adverse events reduced time to appointment and hospitalizations from 61 days to 39 days and from 11% to 2%, respectively, winning Duke Cancer Institute its second ACCC Innovator Award. #immunotherapy #cancercare #telemedicine #accc https://lnkd.in/gab54Si9

Why do cancer patients need "open and honest communication about prognosis" if we have very advanced metastatic solid tumours? So we can participate fully in decisions about the last period of our lives "Question:  Is oncologic treatment of very advanced disease associated with improved survival? "Findings:  In this cohort study of 78 446 adult patients from a nationwide database of patients with 6 common metastatic solid tumors, there was no statistically significant survival benefit for patients treated at practices that used more systemic therapy for very advanced cancer compared with patients treated at practices that used less. "Meaning:  In seeing no improvements in survival among practices with highest rates of treatment for very advanced disease, oncologists may hesitate before offering additional therapy and focus on open and honest communication about prognosis, allowing patients to make informed decisions. "Conclusions and Relevance:  In this cohort study, patients with metastatic or advanced cancer treated at practices with higher NQF 0210 rates did not have improved survival. Future efforts should focus on helping oncologists identify when additional therapy is futile, developing goals of care communication skills, and aligning payment incentives with improved end-of-life care." #cancer #palliativecare #endoflife #patientcommunication

"There were 8297 ovarian cancer decedents. Their mean (SD) age at death was 69.6 (13.1) years, and their mean (SD) oncologic survival was 2.8 (3.9) years. Among 3958 patients with known cancer stage, 3495 (88.3%) presented with stage III or IV disease. One-third of patients (2667 [32.1%]) received late palliative care in the final 3 months of life. Results of multivariable regression analysis indicated that any palliative care initiated earlier than 3 months before death was associated with lower rates of aggressive end-of-life care (odds ratio [OR], 0.47 [95% CI, 0.37-0.60]), death in hospital (OR, 0.54 [95% CI, 0.45-0.65]), and intensive care unit admission (OR, 0.46 [95% CI, 0.27-0.76]). Specialist palliative consultation from 3 months up to 6 monts before death was associated with decreased likelihood of late chemotherapy (OR, 0.46 [95% CI, 0.24-0.88])."

"There were 8297 ovarian cancer decedents. Their mean (SD) age at death was 69.6 (13.1) years, and their mean (SD) oncologic survival was 2.8 (3.9) years. Among 3958 patients with known cancer stage, 3495 (88.3%) presented with stage III or IV disease. One-third of patients (2667 [32.1%]) received late palliative care in the final 3 months of life. Results of multivariable regression analysis indicated that any palliative care initiated earlier than 3 months before death was associated with lower rates of aggressive end-of-life care (odds ratio [OR], 0.47 [95% CI, 0.37-0.60]), death in hospital (OR, 0.54 [95% CI, 0.45-0.65]), and intensive care unit admission (OR, 0.46 [95% CI, 0.27-0.76]). Specialist palliative consultation from 3 months up to 6 monts before death was associated with decreased likelihood of late chemotherapy (OR, 0.46 [95% CI, 0.24-0.88])."

As CEO of Orchid Healthcare Solutions, I am proud to announce our Strategic Partnership with FirstHx. This alliance will bring oncology treatment to all, who are in need of access to quality #cancer outcomes in tangable ways. We look forward to the future of technology advances in oncology and on the leading fore front of change in the design of Oncology outcomes and care delivery. If you would like to learn more about how this Parnership provides impact in Oncology care, please use the link in the announcement below. #Cancer #Canceroutcomes #NursingLeadership #cancercare #partnership OncoDaily CancerX Moonshot

Enhancing Multidisciplinary Team Processes in Lung Cancer Care is crucial for providing the best possible care for patients. Our latest article highlights the importance of Multidisciplinary Teams (MDTs) and outlines the steps involved in the MDT meeting process. This article also sheds light on the challenges faced by MDTs and proposes a self-assessment toolkit to help hospitals improve their MDT processes. Key takeaways from the article include the composition of an optimal MDT, the steps involved in the MDT meeting process, and the challenges faced by MDTs. Read the full article to learn more about how MDTs can improve lung cancer care and why value-based partnerships are crucial. Don't miss out on this valuable information! #lungcancer #MDT #healthcare #cancercare #CollectiveIntelligence #highvaluecare #carepathway #ValueBasedPartnerships #CommunityofPractice

Did you know 87% of patients with low-grade serous ovarian cancer or LGSOC recently surveyed reported being afraid to make long-term plans? And 94% of the survey respondents were worried that their LGSOC would return despite treatment. Today, we unveiled these results from our LGSOC Patient Impact Survey that highlighted the significant negative impact that this rare ovarian cancer has on many aspects of patients' lives. The global survey was developed in partnership with patient advocates and community medical leaders and was presented at the Society of Gynecologic Oncology's Annual Meeting on Women’s Cancer. Read the press release to learn more: https://bit.ly/3IIgM2m #SGOmtg #PowerofSharedPurpose #LGSOC #ovariancancer #LGSOCPatientImpactSurvey 

APAC is the hot bed for HCC…with 80% of the worlds diagnosis and a need to improve mortality rates. Early diagnosis always helps…but is very difficult to do effectively and stay affordable. Tackling this problem is the AHCC - a clinical trial group consisting of 62 pioneering clinical Centres. Their work is showcased here. #oncology #clinicaltrials #oncoshot #oncopericia #cancercare #cancerresearch

Discover how the Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group, led by Protocol Chair Professor Pierce Chow, is tackling the HCC epidemic in the region. With over 25 years of pioneering research, 62 participating centres, and 4,000+ patients enrolled in groundbreaking studies, AHCC is making strides in early diagnosis, innovative treatments, and collaborative efforts to improve patient outcomes. Learn more about their key achievements, ongoing trials, and commitment to advancing HCC care in our latest article. Together, we're driving progress against liver cancer and fostering a spirit of regional cooperation. Read the full article here: https://lnkd.in/gZBJTPA9

Over the last decade, cancer research in Asia has evolved significantly, moving beyond individual hospitals to form consortia that unite leading experts and institutions in an otherwise hyper-fragmented APAC landscape. At Oncoshot, we are excited to support these consortia, exploring new ways to accelerate research and clinical trial opportunities across the region while respecting the needs of both participating institutes and the consortia. Our latest blog post highlights the #Asia-Pacific Hepatocellular Carcinoma (#AHCC) Trials Group, a consortium focused on liver cancer—a critical area of need in Asia, which bears the largest burden of liver cancer globally. The AHCC is making significant strides in research and drug development by bringing together 62 centers across 17 countries, fostering collaboration and innovation in the fight against hepatocellular carcinoma. Learn more about how this consortium is advancing liver cancer care through research and therapeutic trials.